These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11244883)

  • 1. [Vasopeptidase inhibition. A new mechanism of action for the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Internist (Berl); 2001 Feb; 42(2):290-6. PubMed ID: 11244883
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
    MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
    Maniu CV; Meyer DM; Redfield MM
    Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omapatrilat.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
    [No Abstract]   [Full Text] [Related]  

  • 5. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension.
    Alves-Lopes R; Montezano AC; Neves KB; Harvey A; Rios FJ; Skiba DS; Arendse LB; Guzik TJ; Graham D; Poglitsch M; Sturrock E; Touyz RM
    Hypertension; 2021 Sep; 78(3):604-616. PubMed ID: 34304582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
    Pickering TG
    J Clin Hypertens (Greenwich); 2002; 4(5):371-3. PubMed ID: 12368583
    [No Abstract]   [Full Text] [Related]  

  • 9. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Omapatrilat for treatment of heart failure].
    Yamazaki T
    Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
    Nathisuwan S; Talbert RL
    Pharmacotherapy; 2002 Jan; 22(1):27-42. PubMed ID: 11794428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibition and angio-oedema.
    Messerli FH; Nussberger J
    Lancet; 2000 Aug; 356(9230):608-9. PubMed ID: 10968427
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
    Chen HH; Cataliotti A; Burnett JC
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopeptidase inhibitors: a bradykinin link.
    Boix F
    Lancet; 2002 Mar; 359(9312):1157-8. PubMed ID: 11943297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.